All In MedTech

FDA Clearance Tracker · P960009-S438

Master Activa®, Percept and SenSight Deep Brain Stimulation Therapy System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 8, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jan 8, 2024

Approved

Time to decision

497 days

Received Aug 29, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P960009-S438
Device name
Master Activa®, Percept and SenSight Deep Brain Stimulation Therapy System
Applicant location
Minneapolis, MN
Received
Aug 29, 2022
Decided
Jan 8, 2024
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P960009

Device type

Device class
Class III

Every decision under product code MBX

FDA's approval statement

As written in FDA's record.

Approval for the following: For P960009/S438, approval for: • Model B35300 Percept RC Implantable Neurostimulator (INS)• Model RS6230 Recharger Kit (including the WR9230 Recharger)• Model A610 Clinician Programmer Application (PPA) Software (Version 4.0) • Model A620 Patient Programmer Application (CPA) (Version 3.0) • A90300 Recharger Application Software (RAS) (Version 2.0) • Labeling changes in physician and patient labeling for existing products, to be consistent with the proposed labeling for the new Percept RC System.For H020007/S329, approval for: • Model B35300 Percept RC Implantable Neurostimulator (INS)• Model RS6230 Recharger Kit (including the WR9230 Recharger)• Model A610 Clinician Programmer Application (PPA) Software (Version 4.0) • Model A620 Patient Programmer Application (CPA) (Version 3.0) • A90300 Recharger Application Software (RAS) (Version 2.0) • Dystonia Kits (Models 33TH60, 33TH76, and 33TH69) • Labeling changes in physician and patient labeling for existing products, to be consistent with the proposed labeling for the new Percept RC System.For H050003/S289, approval for:• Model A610 Clinician Programmer Application (PPA) Software (Version 4.0) For P840001/S527, approval for: • Labeling changes in physician and patient labeling for existing products, to be consistent with the proposed labeling for the new Percept RC System

Source documents

Other decisions for Medtronic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.